Abstract：
BACKGROUND: The two most common types of breast cancer are invasive or infiltrating ductal carcinoma (IDC) and invasive or infiltrating lobular carcinoma (ILC) (Pestalozzi et al., J. Clin. Oncol., 26, 2008, 3006). Between 5% and 15% of invasive breast carcinomas are lobular carcinomas (Pestalozzi et al., J. Clin. Oncol., 26, 2008, 3006; Dossus and Benusiglio, Breast Cancer Res., 17, 2015, 37; Braunstein et al., Breast Cancer Res. Treat., 149, 2015, 555). The paucity of data relating to recurrence rates of lobular cancers prompted this study.
METHODS: A retrospective cohort study of all cases of lobular breast carcinoma reported to the Western Australia Cancer Registry with the clinical and pathological details between 2000 and 2014.
RESULTS: Overall, 2463 subjects with a total of 2526 events of invasive lobular carcinoma of the breast. 11/2463 (0.45%) subjects met criteria for local recurrence of invasive lobular breast cancer, with an incidence of 1 in 224.
CONCLUSIONS: There are clinical implications for the management and follow-up for patients with a diagnosis of lobular cancer of the breast. Due to the low recurrence rate, now, the standard practice in our institution does not offer magnetic resonance imaging (MRI) as part of the follow-up for ILC patients. Other centres should establish local recurrence rates to aid development of appropriate management protocols.
METHODS: A retrospective cohort study of all cases of lobular breast carcinoma reported to the Western Australia Cancer Registry with the clinical and pathological details between 2000 and 2014.
RESULTS: Overall, 2463 subjects with a total of 2526 events of invasive lobular carcinoma of the breast. 11/2463 (0.45%) subjects met criteria for local recurrence of invasive lobular breast cancer, with an incidence of 1 in 224.
CONCLUSIONS: There are clinical implications for the management and follow-up for patients with a diagnosis of lobular cancer of the breast. Due to the low recurrence rate, now, the standard practice in our institution does not offer magnetic resonance imaging (MRI) as part of the follow-up for ILC patients. Other centres should establish local recurrence rates to aid development of appropriate management protocols.
摘要：
背景：两种最常见的乳腺癌类型是浸润性或浸润性导管癌（IDC）和浸润性或浸润性小叶癌（ILC）（Pestalozzi等人。,J.Clin.Oncol.,26,2008,3006)。5％至15％的浸润性乳腺癌是小叶癌（Pestalozzi等人。,J.Clin.Oncol.,26，2008，3006；Dossus和Benusiglio，乳腺癌研究。,17，2015，37；Braunstein等人。,乳腺癌研究。请便.,149,2015,555)。缺乏与小叶癌复发率相关的数据促使了这项研究。
方法：一项回顾性队列研究，研究了2000年至2014年间向西澳大利亚州癌症登记处报告的所有小叶状乳腺癌病例的临床和病理细节。
结果：总体而言，2463名受试者,总共2526例乳腺浸润性小叶癌事件。11/2463（0.45%）受试者符合浸润性小叶乳腺癌局部复发标准，发病率为224分之一。
结论：对诊断为乳腺小叶癌的患者的治疗和随访有临床意义。由于复发率低，现在,我们机构的标准实践不提供磁共振成像(MRI)作为ILC患者随访的一部分.其他中心应确定当地复发率，以帮助制定适当的管理方案。
方法：一项回顾性队列研究，研究了2000年至2014年间向西澳大利亚州癌症登记处报告的所有小叶状乳腺癌病例的临床和病理细节。
结果：总体而言，2463名受试者,总共2526例乳腺浸润性小叶癌事件。11/2463（0.45%）受试者符合浸润性小叶乳腺癌局部复发标准，发病率为224分之一。
结论：对诊断为乳腺小叶癌的患者的治疗和随访有临床意义。由于复发率低，现在,我们机构的标准实践不提供磁共振成像(MRI)作为ILC患者随访的一部分.其他中心应确定当地复发率，以帮助制定适当的管理方案。
